BLTE

Belite Bio, Inc

Insider Trades

NameValueActionPriceCurrent Price
Scholl Hendrik PeterChief Medical Officer
$707k4.9k shares
SellJun 18, 2026
$145.43
$147.07
Scholl Hendrik PeterChief Medical Officer
$542k3.7k shares
SellJun 18, 2026
$144.66
$147.07
Scholl Hendrik PeterChief Medical Officer
$175k1.2k shares
SellJun 18, 2026
$146.24
$147.07
Scholl Hendrik PeterChief Medical Officer
$14k96 shares
SellJun 18, 2026
$147.11
$147.07
Scholl Hendrik PeterChief Medical Officer
$14k96 shares
SellJun 18, 2026
$143.90
$147.07
Scholl Hendrik PeterChief Medical Officer
$438k3.1k shares
SellJun 16, 2026
$139.57
$147.07

News

globenewswire.comBelite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1globenewswire.comJun 12globenewswire.comBelite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1globenewswire.comJun 12seekingalpha.comBelite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 8globenewswire.comBelite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conferenceglobenewswire.comJun 2seekingalpha.comBelite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 20